In memoriam: Frederick E Hargreave (1938-2011)
O'Byrne, P.M.; Nair, P.; Sterk, P.J.

Published in:
Thorax

DOI:
10.1136/thoraxjnl-2011-201141

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
In memoriam: Frederick E Hargreave (1938–2011)

A wonderful clinical scientist, great friend and mentor to many in the field of respiratory medicine, Frederick E Hargreave (known to everyone as Freddy), died suddenly on 15 June 2011. Freddy was born in Hong Kong and completed his medical school training at the University of Leeds. After completing his initial clinical training, Freddy moved to London to work as a house officer in respiratory medicine with Dr EJ Moran Campbell at the Hammersmith Hospital. A short while later, Moran Campbell accepted the position as the founding chair of the Department of Medicine at the Faculty of Health Sciences at McMaster University in Hamilton, Ontario, a move that was to change Freddy’s life both personally and professionally. Subsequently, Freddy began his research training with Professor Jack Pepys at the Brompton Hospital. During this time, Freddy described a new clinical entity, bird fancier’s lung disease, a type of allergic alveolitis caused by the inhalation of bird antigens.1

In 1969, Freddy Hargreave joined the Department of Medicine at McMaster University, at the behest of Moran Campbell and his fellow, who described the methodology for the measurement of airway hyper-responsiveness in asthma,2 had demonstrated that this was a crucial component of the disease and present in all patients with current symptoms and determined that the degree of airway hyper-responsiveness was related to the amount of treatment needed to manage asthma.3 The paper describing this methodology4 is a citation classic, having been cited almost 1800 times.

Other studies conducted in his laboratory, during this time, described a method for allergen inhalation challenge5 (cited almost 900 times), which remains widely used still to examine mechanisms of allergen-induced airway responses. Also, his studies demonstrated that allergen inhalation could change airway responsiveness for up to several weeks and that this was particularly obvious in subjects who developed allergen-induced early and late phase responses.6 The changes in airway responsiveness were also seen in patients with occupational asthma.7

In the early 1980s, the importance of persistent airway inflammation in the pathogenesis of asthma became apparent. The type of inflammatory response differed from patient to patient and was difficult to measure because it required fiberoptic bronchoscopy7 and could not be done routinely. The brilliance of Freddy Hargreave’s research was that it was always focused at directly solving patient-related issues. He recognised that the non-invasive measurement of airway inflammation was a critical step in the evaluation and treatment of patients with difficult-to-treat asthma. This resulted in the development of the methodology for sputum induction and measurement of inflammatory cells in sputum.8 Almost immediately, this resulted in the identification of a new syndrome—persistent eosinophilic airway inflammation in the absence of asthma9—that accounts for about 10% of patient referrals with chronic persistent cough to respiratory clinics.10

In his research, Freddy did not aspire to be the very first with a discovery, but he passionately strived to provide the most accurate data. The standardised methods that Freddy’s laboratory developed for sputum induction and processing11 are now considered the gold standard and used as a research tool in all laboratories that conduct clinical research in asthma; however, from extensive experience in measuring sputum inflammatory cells in the clinical setting, Freddy was convinced of its added value in the everyday management of difficult-to-control asthma. Clinical trials comparing standard guideline directed management of asthma with a management scheme, which added the routine measurement of induced sputum, showed a dramatic advantage of adding the sputum method in reducing the risks of severe asthma exacerbations and also in determining the appropriate doses of inhaled and/or oral corticosteroids to manage these patients.12 In addition, using induced sputum allowed the identification of a group of patients (about half of those with difficult-to-treat asthma) who greatly benefit from the use of a monoclonal antibody directed against interleukin 5.13 Some, but not all, tertiary level asthma clinics worldwide have embraced this methodology; based on this evidence and a driving ambition until his untimely death, he wanted to extend the use of this method to benefit patients. His contribution to asthma care has been recognised by several honorary lectureships and an honorary degree from the University of Modena in 2010.

His research inquisitiveness was complemented by his extraordinary qualities as a caring physician. He showed deep
empathy and a genuine concern for all his patients. He listened intently to their problems and demonstrated extraordinary patience and skill in eliciting a history particularly in patients with occupational lung diseases. He would also show extreme tenacity to get to the root of problems and getting investigations done to establish accurate diagnosis. In the current era of technology-driven medical practice, watching Freddy elicit a careful history and establishing a diagnosis with minimal investigation after a thorough physical examination, was a real treat for his fellows.

Freddy Hargrave’s brilliance as a clinical scientist was only eclipsed by his skills as a mentor. He embodied every quality expected of a mentor. He provided his trainees with extraordinary supervision, unselfish love and affection and trained them with the expectation that they would be not just as good as he was, but to be better than him. Many of the research leaders in asthma in Canada have trained at his laboratory at the Firestone Institute and his previous fellows are research leaders in more than 20 countries. Freddy was also genuinely interested in international research developments and was among the first North American respiratory scientists who actively and consistently participated in the European Respiratory Society. His openness to colleagues around the world made him highly respected, beloved and led to an unprecedented acceleration of the research field. Freddy’s implicit confidence in his long list of trainees made them flourish. The nicest aspect was that he hardly realised that any of this was exceptional.

His honesty, integrity and precision in research were legendary and he tried to impart these qualities to his trainees. He had the skill of real listening. His supervision extended beyond clinical and research training. He paid particular attention to ensure that his fellows were trained in literary skills, writing skills, grammar and semantics, often insisting that manuscripts be drafted time and time again to ensure perfection. He was singularly insistent on the use of nominalism to define diseases such as asthma and argued that essentialist definitions did not have a place in scientific discussions.\(^1\)\(^2\) In addition to making landmark advancements in the diagnosis and treatment of asthma and other obstructive airway diseases, he mentored his trainees to be world-class accomplishments, he did not care for titles, accolades or his own advancement. To his patients, he was not Dr Hargrave, but Freddy—the doctor and friend who wore shorts, sandals and knee high socks, even in the depth of winter. There never has been and probably never will be a physician whose phone and home were always open to anyone in need. He cared genuinely, and in everything he did, he brought a level of decency that many overlook.

Paul M O’Byrne,\(^1\) Parameswaran Nair,\(^1\) Peter J Sterk\(^2\)

\(^1\)Firestone Institute for Respiratory Health and McMaster University, Hamilton, Ontario, Canada; \(^2\)The Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Correspondence to Professor Paul M O’Byrne, Department of Medicine, McMaster University Medical Center, 1200 Main St. West, Hamilton, ON L8N 3Z5, Canada; obynep@mcmaster.ca

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

Published Online First 13 October 2011


REFERENCES

In memoriam: Frederick E Hargreave (1938–2011)

Paul M O’Byrne, Parameswaran Nair and Peter J Sterk

Thorax 2011 66: 1101-1102 originally published online October 13, 2011
doi: 10.1136/thoraxjnl-2011-201141

Updated information and services can be found at:
http://thorax.bmj.com/content/66/12/1101.full.html

These include:

References
This article cites 14 articles, 4 of which can be accessed free at:
http://thorax.bmj.com/content/66/12/1101.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1391 articles)
- Inflammation (767 articles)
- Cardiothoracic surgery (462 articles)
- Interstitial lung disease (348 articles)
- Occupational and environmental medicine (89 articles)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/